| Type | Title | Date Released | |
|---|---|---|---|
6-K/A | Form 6-K/A | ||
6-K | ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences | ||
6-K | ProQR Appoints Chris Hart as Chief Data and AI Officer and Thomas Wolf to Board as Strategic AI Advisor | ||
6-K | ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases | ||
6-K | ProQR Therapeutics N.V. Reports Financial Results for the Six Months Ended June 30, 2026 | ||
6-K | ProQR Therapeutics Reports Q2 2026 Financial Results and Clinical Progress | ||
4 | de Boer Daniel Anton (Reporting) | ||
SCHEDULE 13D/A | VAN HERK INVESTMENTS B.V. (Filed by) | ||
SCHEDULE 13G | Aberdeen Group plc (Filed by) | ||
SCHEDULE 13G/A | ELI LILLY & Co (Filed by) | ||
4 | Filius Bart (Reporting) | ||
EFFECT | Form EFFECT |
